BioPontis Announces Collaboration with Massachusetts General Hospital on Huntington’s disease

BioPontis Announces Collaboration with Massachusetts General Hospital on Huntington’s disease

BioPontis Alliance and Massachusetts General Hospital are announcing a joint research collaboration targeting the treatment of Huntington’s disease (HD), a progressive, genetic brain disorder. According to the Huntington’s Disease Society of America (HDSA), the symptoms of HD can feel like having amyotrophic lateral sclerosis (ALS), Parkinson’s and Alzheimer’s all in one. Link to details of this collaboration below:

English

Dutch

French


About BioPontis Alliance for Rare Diseases

BioPontis Alliance for Rare Diseases is a 501c(3) public charity in the US (North Carolina) and a foundation of public utility (fup/son) in Belgium (Brussels). Managed by an international Board and executive team, BioPontis partners with patient organizations and clinical researchers to bridge the gap between promising science and new medicines. BioPontis Alliance for Rare Diseases is being established as a global non-profit, inviting corporate, private and foundation philanthropic support. More information, including how contributions to support our programs and mission can be made, at http://biopontisalliance.org.

 

Contacts:

Erik Tambuyzer, Chairperson BioPontis Alliance for Rare Diseases
+32 475 61 57 11 (Brussels, Belgium)
Erik.Tambuyzer@biopontisalliance.org

Richard Basile, CEO BioPontis Alliance for Rare Diseases
+1 919 345 5386 (Raleigh, USA)
Richard.Basile@biopontisalliance.org